Asian expansion – Venture Valuation is taking advantage of growth in Asia opening a new office in Singapore

Asian expansion – Venture Valuation is taking advantage of growth in Asia opening a new office in Singapore

ZURICH / SINGAPORE, December 2013 – Venture Valuation has recently opened its Asian office in Singapore to take advantage of the growing life sciences sector in Asia and to be even closer to its customers.

Having had clients from China, India, Japan, Korea and Singapore, Venture Valuation has opened up an office in one of the region’s most active life sciences centers – Singapore. Venture Valuation is offering company and product valuations to the growing number of investors in the Asia Pacific market. Especially family offices looking to invest in health care related businesses will benefit from the know-how and 14 years experience of Venture Valuation providing independent valuation services. Also Venture Capital and Corporate Investors as well as technology transfer offices have now the opportunity to work with Venture Valuation in the region. For emerging companies Venture Valuation will be able to provide valuation services for equity investments but also for M&A activities. For any in- or out-licensing, Venture Valuation offers its tailored product valuations.

Beside the valuation services, Venture Valuation offers its global Life Sciences database, Biotechgate with over 30’000 company profiles, licensing opportunities, financing rounds, management details and pipeline products. Asian companies looking for in-licensing of North American or European products will find opportunities not available in any other database or directory. Biotechgate focuses on the smaller, private companies and thus has a unique offering of dataset.

Venture Valuation can now provide the perfect bridge between Asia, Europe and North America, having offices on all three continents. As biotech, life sciences and health care are international industries, Venture Valuation can offer a truly global coverage and experience.

For further information: Dr. Patrik Frei, CEO, p.frei (at) venturevaluation.com

Venture Valuation AG
Kasernenstrasse 11
CH-8004 Zurich
Switzerland
Phone: +41 43 321 86 60

Venture Valuation VV Asia Pte. Ltd.
165 Bukit Merah Central, #05-3679
Singapore 150165
Phone: +65 (94) 570 580

About us:

Venture Valuation (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries. Furthermore, Venture Valuation has initiated, maintains and provides the Biotech and Life Sciences Database Biotechgate (www.biotechgate.com), along with many country databases including in Canada (www.canadianlifesciences.com), France (www.frenchbiotech.com), Germany (www.germanbiotech.com), Scandinavia (www.scandinavianlifesciences.com), Switzerland (www.swisslifesciences.com), UK (www.ukbiotech.com) and the US (www.usalifesciences.com).

Click here to download this press release – 2 pages

Leave a Reply

Your email address will not be published. Required fields are marked *